Vaughan, GB
Adrian St Vaughan, Weybridge GB
Patent application number | Description | Published |
---|---|---|
20120025111 | ELECTROMAGNETIC FIELD ABSORBING COMPOSITION - This invention relates to the field of an electromagnetic (EM) field absorbing composition, in particular, those capable of providing absorbance in the frequency of commercial radar. The composition finds particular use as a radar absorbing coating for wind turbines, in particular for use in onshore and offshore environments. There are further provided coated surfaces comprising the composition, methods of absorbing EM radiation, and methods of use of such a composition, such that a surface coated in the composition is capable of absorbing EM radiation. There is provided an electromagnetic radiation absorbing composition comprising elongate carbon elements with an average longest dimension in the range of 50 to 1 000 microns, with a thickness in the range of 1 to 15 microns and present in the range of from 0.5 to 20 volume % dried, in a non conductive binder. | 02-02-2012 |
Aidan Paul Vaughan, Cardiff GB
Patent application number | Description | Published |
---|---|---|
20140234125 | SYRINGELESS FILTER DEVICE COMPRESSOR - The disclosure relates to an in-hand operable compressor | 08-21-2014 |
Alun Vaughan, Winchester GB
Patent application number | Description | Published |
---|---|---|
20130175068 | Recyclable Thermoplastic Insulation with Improved Breakdown Strength - The disclosure provides a process for producing a material with improved break-down strength. The process includes heating a polymeric composition composed of a low density polyethylene (LDPE) and a minority amount of a high density polyethylene (HDPE). The polymeric composition is heated to at least the melting temperature of the HDPE. The process includes control-cooling the heated polymeric composition at a cooling rate from 0.1° C./min to 20° C./min, and forming a polymeric composition. The control-cooled polymeric composition has a unique morphology which improves breakdown strength. Also provided is a coated conductor with an insulating layer composed of the polymeric composition with the unique morphology. The insulating layer exhibits improved breakdown strength. | 07-11-2013 |
20150087787 | POLYPROPYLENE BLENDS AND PROCESSES FOR PRODUCING POLYMERIC COMPOSITIONS - Polymer blends of polypropylene homopolymer and propylene-α-olefin interpolymer. Processes for producing polymeric compositions comprising control-cooling heated blends of polypropylene and propylene-α-olefin interpolymer. Such polymeric compositions can be employed in forming coated wires and cables. | 03-26-2015 |
Benjamin Nicholas Gray Vaughan, Glasgow GB
Patent application number | Description | Published |
---|---|---|
20110131496 | SELECTION OF CONTENT TO FORM A PRESENTATION ORDERED SEQUENCE AND OUTPUT THEREOF - A method of selecting content to form a content presentation, the presentation comprising an ordered sequence of selected amounts of content, there being a plurality of items of content available for the presentation, the method comprising: (a) for each of the items of content, determining an associated weight-value based, at least in part, on one or more parameters for the presentation; (b) performing a weighted selection of one of the items of content, the selection being weighted in accordance with the weight-values associated with the items of content; (c) selecting at least a part of the content of the selected item of content to be one of the amounts of content in the ordered sequence of selected amounts of content; and (d) repeating steps (a), (b) and (c) until the presentation is complete. | 06-02-2011 |
David A. Vaughan, Bristol GB
Patent application number | Description | Published |
---|---|---|
20100088125 | System and Method for Automation and Management of Insurance Claims Processing and Post Placement Transactions - A system and method is provided to, for example, manage the process of settling an insurance transaction over a computer network. The management environment is designed to promote collaboration between parties involved in an insurance transaction settlement process by use of defined workflows, digital storage of policy of claim data, and allowing parties to view data and interoperably communicate and transact through the management environment. The management environment serves to improve communication between the parties involved in the insurance transaction settlement process and to reduce costs. | 04-08-2010 |
John Vaughan, Derbyshire GB
Patent application number | Description | Published |
---|---|---|
20090269003 | FIBRE OPTIC SWEAT SENSOR - A sensor for sweat or other aqueous discharge onto skin comprises a plastic optical fibre comprising a core and cladding, said core being in intimate contact at a first end with a light emitter and at a second end with a light detector, and said fibre having a sensing zone in which the cladding is replaced by a water-permeable translucent biocompatible polymer containing dispersed therein a biocompatible indicator that varies the intensity of an optical signal at a selected wavelength depending on whether the indicator is wet or dry. Such a sensor permits real time monitoring of sweating or other discharge, and can also enable electronic recording and/or remote monitoring. | 10-29-2009 |
Laura Jane Vaughan, Eglinton GB
Patent application number | Description | Published |
---|---|---|
20130240617 | Device and System for Providing a Visual Representation of Product Contents Within a Package - A method and an associated system for providing on a wireless communication device an image representing contents of a package, the method comprising the steps of reading a readable code on the package using a camera on the wireless communication device, displaying the image representing the contents of the package on the wireless communication device when the camera is positioned to view at least a portion of the package, the image being superimposed on a view of the package, and altering the image in response to relative movement between the package and the camera such that the image displayed on the wireless communication device represents the portion of the contents of the package at which the camera is pointed. | 09-19-2013 |
20130246136 | Device, System and Method For Facilitating Interaction Between A Wireless Communcation Device and a Package - A method of providing a personalized experience on a wireless communication device corresponding to the contents of a package, the package containing a product may include the steps of reading a unique code on a package, the package containing a product, displaying a personalized illusory images on the wireless communication device, and altering the personalized illusory images in response to relative movement between the package and the camera. | 09-19-2013 |
20140084003 | Can Ends Having Machine Readable Information - A system and method for laser marking can end, including a can end center panel and/or pull tab. The decorated can end and/or tabs may have a machine readable image. | 03-27-2014 |
Lesley-Ann Vaughan, Harston GB
Robert Vaughan, London GB
Patent application number | Description | Published |
---|---|---|
20140178857 | Method - The invention provides a method of detecting the presence of anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and detecting the binding or absence of binding of antibodies to said recombinant MHC molecules. This method allows the detection and/or identification of one or more specific MHC particularly HLA allele antibodies. | 06-26-2014 |
20140273267 | Methods of depleting antibodies directed towards major histocompatibility complex - The invention provides a method of depleting anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and removing at least the recombinant MHC molecules to which antibodies to said recombinant MHC molecules contained within the sample have bound. This method allows the depletion of one or more specific MHC particularly HLA allele antibodies from a sample. | 09-18-2014 |
20150260622 | METHODS OF DEPLETING ANTIBODIES DIRECTED TOWARDS MAJOR HISTOCOMPATIBILITY COMPLEX - The invention provides a method of depleting anti-MHC antibodies in a sample comprising contacting said sample with one or more recombinant MHC molecules or functionally equivalent variants, derivatives or fragments thereof and removing at least the recombinant MHC molecules to which antibodies to said recombinant MHC molecules contained within the sample have bound. This method allows the depletion of one or more specific MHC particularly HLA allele antibodies from a sample. | 09-17-2015 |
Ross Vaughan, Staffordshire GB
Patent application number | Description | Published |
---|---|---|
20140243754 | APPARATUS FOR INTRAOCULAR INJECTION - Described is an apparatus for intraocular injection comprising an inner sleeve adapted to accommodate a syringe having a needle, a needle cover adapted to cover the needle, and an outer sleeve telescopically coupled to the inner sleeve. The inner sleeve includes a distal end adapted to engage the needle cover. Movement of the inner sleeve relative to the outer sleeve causes removal of the needle cover from the needle. | 08-28-2014 |
20150272778 | APPARATUS FOR INTRAOCULAR INJECTION - Described is an apparatus for intraocular injection comprising a body adapted to accommodate a syringe having a needle, a needle cover adapted to cover the needle, and two or more resilient arms extending distally from the body. The body has a longitudinal axis. The arms are adapted to selectively engage the needle cover. | 10-01-2015 |
Ross Vaughan, Cheshire GB
Patent application number | Description | Published |
---|---|---|
20140039391 | APPARATUS FOR INTRAOCULAR INJECTION - An apparatus for intraocular injection comprising a body adapted to accommodate an injection device, a displacement device coupled to a distal end of the body, and a sleeve coupled to the body and axially moveable relative to the body. The displacement device includes at least one rotatable member adapted to contact a superficial layer of an eye, and the sleeve engages and causes rotation of the at least one rotatable member as the sleeve moves from a first axial position to a second axial position. Rotation of the at least one rotatable member displaces the superficial layer relative to an underlying layer of the eye. | 02-06-2014 |
Simon Vaughan, Banchory GB
Patent application number | Description | Published |
---|---|---|
20130277589 | SUBSEA VALVE SEAT ARRANGEMENTS - A subsea valve comprises a valve gate ( | 10-24-2013 |
Steven Bradley Vaughan, Yorkshire GB
Patent application number | Description | Published |
---|---|---|
20110009032 | Deburring Medium and Process - A vibratory finishing medium element having at least a portion comprising a devitrified material. | 01-13-2011 |
Tristan Vaughan, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20100003259 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 01-07-2010 |
20100111953 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 05-06-2010 |
20110117093 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 05-19-2011 |
20110293610 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 12-01-2011 |
20120121606 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 05-17-2012 |
Tristan J. Vaughan, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20090155205 | HUMAN ANTIBODIES THAT BIND HUMAN TNFa - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 06-18-2009 |
20100016557 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 01-21-2010 |
20100040604 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 02-18-2010 |
20120178107 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 07-12-2012 |
20120219564 | Human Antibodies That Bind Human TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 08-30-2012 |
20120258114 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 10-11-2012 |
20130115224 | METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 05-09-2013 |
20130122018 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 05-16-2013 |
20130330356 | METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 12-12-2013 |
20130330357 | METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 12-12-2013 |
Tristan John Vaughan, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20120270265 | METHODS OF OBTAINING A SPECIFIC BINDING MEMBER THAT BINDS EOTAXIN - Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy. | 10-25-2012 |
20140294857 | METHODS OF OBTAINING A SPECIFIC BINDING MEMBER THAT BINDS EOTAXIN - Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy. | 10-02-2014 |
Victor Ralph Vaughan, Derbyshire GB
Patent application number | Description | Published |
---|---|---|
20100143653 | PROCESS OF FORMING A POLYMERIC PRODUCT CONTAINING CREMATION ASHES - The present invention relates to a method of forming a cremation ashes-containing polymer product, comprising the steps of: (i) providing cremation ashes, (ii) washing the cremation ashes in a medium, and (iii) combining the washed ashes with a polymerisable agent and/or polymer melt to form a cremation ashes-containing polymer product. Polymer products obtained by the method, or articles made from them, provide a unique and permanent keepsake of a deceased person or pet. | 06-10-2010 |